[{"address1": "321 Harrison Avenue", "address2": "5th floor", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 213 5054", "website": "https://www.hillevax.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 90, "companyOfficers": [{"maxAge": 1, "name": "Dr. Robert M. Hershberg M.D., Ph.D.", "age": 61, "title": "Co-Founder, President, CEO & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1035100, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1733011200, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.83, "open": 1.85, "dayLow": 1.83, "dayHigh": 1.935, "regularMarketPreviousClose": 1.83, "regularMarketOpen": 1.85, "regularMarketDayLow": 1.83, "regularMarketDayHigh": 1.935, "beta": 0.773, "forwardPE": -1.1548347, "volume": 533494, "regularMarketVolume": 533494, "averageVolume": 199810, "averageVolume10days": 391230, "averageDailyVolume10Day": 391230, "bid": 1.83, "ask": 1.87, "bidSize": 300, "askSize": 400, "marketCap": 92639344, "fiftyTwoWeekLow": 1.55, "fiftyTwoWeekHigh": 20.22, "fiftyDayAverage": 1.8885, "twoHundredDayAverage": 6.97315, "currency": "USD", "enterpriseValue": -74621104, "floatShares": 24345325, "sharesOutstanding": 49806100, "sharesShort": 1214030, "sharesShortPriorMonth": 1178235, "sharesShortPreviousMonthDate": 1730332800, "dateShortInterest": 1732838400, "sharesPercentSharesOut": 0.024400001, "heldPercentInsiders": 0.17108999, "heldPercentInstitutions": 0.7527, "shortRatio": 8.84, "shortPercentOfFloat": 0.1509, "impliedSharesOutstanding": 49806100, "bookValue": 3.821, "priceToBook": 0.48678356, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -150280000, "trailingEps": -3.09, "forwardEps": -1.87, "enterpriseToEbitda": 0.557, "52WeekChange": -0.88468695, "SandP52WeekChange": 0.2421279, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "HLVX", "underlyingSymbol": "HLVX", "shortName": "HilleVax, Inc.", "longName": "HilleVax, Inc.", "firstTradeDateEpochUtc": 1651239000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ad85351d-ccca-3533-9e30-baa1f712efa8", "messageBoardId": "finmb_1680788968", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.86, "targetHighPrice": 5.0, "targetLowPrice": 2.0, "targetMeanPrice": 3.0, "targetMedianPrice": 2.5, "recommendationKey": "none", "numberOfAnalystOpinions": 4, "totalCash": 189310000, "totalCashPerShare": 3.925, "ebitda": -134042000, "totalDebt": 24973000, "quickRatio": 13.682, "currentRatio": 14.251, "debtToEquity": 13.552, "returnOnAssets": -0.28904, "returnOnEquity": -0.62240005, "freeCashflow": -85403872, "operatingCashflow": -112209000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-12-21"}]